Neurocrine Biosciences Maps 2026 Execution, “Data-Rich” 2027; Ingrezza Guides $2.7B–$2.8B

Gano said Ingrezza, now in its eighth year of commercialization, produced $2.51 billion in 2025 revenue, up about 9% year over year, with “double-digit volume growth” and record new prescriptions (NRX) across multiple quarters. He noted a headwind in 2025 related to gross-to-net and net price per script tied to contracts taken on during the year, but said the company expects a “clean year” in 2026 from a contracting and access perspective.On the commercial side, Gano said the company generated “just north o ...